<DOC>
	<DOCNO>NCT00419341</DOCNO>
	<brief_summary>The objective study ass efficacy , tolerability , safety pharmacokinetics IgPro20 patient primary humoral immunodeficiency ( PID ) .</brief_summary>
	<brief_title>Study Subcutaneous Immunoglobulin Patients With PID Requiring IgG Replacement Therapy</brief_title>
	<detailed_description>The entire study consist 12-week wash-in/wash-out period follow 12-month treatment period . Pharmacokinetic ( PK ) parameter assess sub-group subject .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Male female age 2 75 year Subjects primary humoral immunodeficiency , namely diagnosis : CVID ( Common Variable Immunodeficiency ) define PAGID ( PanAmerican Group Immunodeficiency ) ESID ( European Society Immunodeficiencies ) XLA ( Xlinked Agammaglobulinemia ) Written informed consent Newly diagnose PID Evidence active serious infection time screen ( i.e. , limit : bacteremia/septicemia , pneumonia , fungal osteomyelitis ) Malignancies lymphoid cell lymphocytic leukemia , NonHodgkin 's lymphoma immunodeficiency thymoma Known hyperprolinemia Hypoalbuminemia , proteinlosing enteropathy , proteinuria Allergic reaction immunoglobulins blood product Known antibody Immunoglobulin A ( IgA ) The subject receive steroid ( oral parenteral , daily â‰¥ 0.15 mg prednisone equivalent/kg/day ) systemic immunosuppressant Female pregnant , breast feeding planning pregnancy course study Participation study investigational product ( IVIG ) within 1 month prior enrollment A positive result screen follow viral marker : Human Immunodeficiency Virus ( HIV ) , Hepatitis C virus ( HCV ) Hepatitis B virus ( HBV ) Aspartate aminotransferase ( ASAT ) Alanine aminotransferase ( ALAT ) concentration &gt; 2.5 time upper normal limit ( UNL ) Creatinine concentration &gt; 1.5 time UNL Any condition likely interfere evaluation study drug satisfactory conduct trial</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Immune globulin subcutaneous</keyword>
	<keyword>SCIG</keyword>
	<keyword>Primary immunodeficiency</keyword>
	<keyword>PID</keyword>
</DOC>